260 related articles for article (PubMed ID: 25809144)
1. Immunological risks of minimization strategies.
Snanoudj R; Tinel C; Legendre C
Transpl Int; 2015 Aug; 28(8):901-10. PubMed ID: 25809144
[TBL] [Abstract][Full Text] [Related]
2. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
3. The need for minimization strategies: current problems of immunosuppression.
Bamoulid J; Staeck O; Halleck F; Khadzhynov D; Brakemeier S; Dürr M; Budde K
Transpl Int; 2015 Aug; 28(8):891-900. PubMed ID: 25752992
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
Camilleri B; Bridson JM; Halawa A
Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
[TBL] [Abstract][Full Text] [Related]
7. The use of novel diagnostics to individualize immunosuppression following transplantation.
Schlickeiser S; Boës D; Streitz M; Sawitzki B
Transpl Int; 2015 Aug; 28(8):911-20. PubMed ID: 25611562
[TBL] [Abstract][Full Text] [Related]
8. Immune minimization strategies in renal transplantation.
Brar JE; Nader ND
Immunol Invest; 2014; 43(8):807-18. PubMed ID: 25296235
[TBL] [Abstract][Full Text] [Related]
9. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation.
Golshayan D; Pascual M
Transpl Immunol; 2008 Nov; 20(1-2):21-8. PubMed ID: 18775494
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
Kamar N; Del Bello A; Belliere J; Rostaing L
Transpl Int; 2015 Aug; 28(8):928-37. PubMed ID: 25557802
[TBL] [Abstract][Full Text] [Related]
11. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function.
Nojima M; Yamada Y; Higuchi Y; Shimatani K; Kanematsu A; Yamamoto S
Transplant Proc; 2017; 49(1):41-44. PubMed ID: 28104155
[TBL] [Abstract][Full Text] [Related]
13. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits.
Meier-Kriesche HU
Curr Opin Nephrol Hypertens; 2006 Jun; 15 Suppl 1():S1-5. PubMed ID: 16829733
[TBL] [Abstract][Full Text] [Related]
15. Long-term maintenance therapy with calcineurin inhibitors: an update.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
[TBL] [Abstract][Full Text] [Related]
16. Are calcineurin inhibitors-free regimens ready for prime time?
Vincenti F
Kidney Int; 2012 Nov; 82(10):1054-60. PubMed ID: 22622502
[TBL] [Abstract][Full Text] [Related]
17. Out with the old, in with the new: immunosuppression minimization in children.
Sarwal MM
Curr Opin Organ Transplant; 2008 Oct; 13(5):513-21. PubMed ID: 19060535
[TBL] [Abstract][Full Text] [Related]
18. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression and Graft Rejection in Living-related HLA-identical Renal Transplantation: The RADOVFULL Study.
Ossman R; Jamme M; Moulin B; Legendre C; Morelon E; Frimat L; Hourmant M; Durrbach A; Malvezzi P; Rostaing L; Luc Taupin J; Mesnard L; Rondeau E;
Transplantation; 2020 Jun; 104(6):1256-1262. PubMed ID: 31465001
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression Minimization and Avoidance Protocols: When Less Is Not More.
Prashar R; Venkat KK
Adv Chronic Kidney Dis; 2016 Sep; 23(5):295-300. PubMed ID: 27742383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
